Company profilePharmaceutical#781 of 1,318 in Pakistan✓ No DRAP alerts

Hoechst Pakistan Limited DSL: 650

Pharmaceutical company · 10 brands · 18 molecules

Ranked #23 of 40 companies in Blood Conditions

10 registered products 12 pharmaceutical brands 18 distinct molecules 0 DRAP alerts

Company overview

10
registered products
12
pharmaceutical brands
18
distinct molecules
3
therapeutic classes
0
DRAP alerts

Hoechst Pakistan Limited DSL: 650 is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 10 product registrations across 18 distinct molecules. Its portfolio is concentrated in Blood Conditions and Antithrombotic Agents. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Hoechst

10 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

10
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
202610

Top molecules by brand count

Tetanus Toxoid ...... Not Less Than 20 Iu1 brand
Not Less Than 40 Iu Iu1 brand
Three Strains Of Influenza Virus ...... 15 Mcg Ha1 brand
Enoxaparin1 brand
Oxaliplatin ...... 5 Mg1 brand
Docetaxel ...... 80 Mg1 brand
Docetaxel ...... 20 Mg1 brand
Insulin Glargine ...... 100 Iu1 brand

Therapeutic classes

Blood Conditions · 1Antithrombotic Agents · 1Diabetes · 1

Conditions treated

Blood Clot/Thrombotic Disorder · 1Insulins · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official15 products · Rs 1,293.24 – Rs 47,565.83
DVAGO4 products · Rs 1,694.92 – Rs 2,766.46
Servaid4 products · Rs 936.26 – Rs 5,656.95
Median across source: Rs 2,126.17

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Himmel Pharmaceuticals Private Limited holds 33 molecules not in this portfolio
AbirateroneAfatinibAfatinib DimaleateAlbuminBortezomibCaspofungin
Hoechst Pakistan Limited holds 5 molecules not in this portfolio
Cefotaxime SodiumCeftriaxoneFludarabineInactivated Type 1 Poliomyelitis VirusMetformin
MACTER INTERNATIONAL (PVT) LTD. holds 178 molecules not in this portfolio
000 I.U10Ug Polysaccharides Covalently Bound To 20Ug To 32Ug Of Tetanus ToxoidAlbendazoleAlbuterolAlfacalcidolAluminium Hydroxide

Get the full profile for Hoechst

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.